A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and
Tolerability of Pembrolizumab in Participants with Recurrent or
Metastatic Cutaneous Squamous Cell Carcinoma (629), NCT03284424
PURPOSE OF THIS CLINICAL RESEARCH TRIAL:
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in adult participants with recurrent or metastatic cutaneous Squamous Cell Carcinoma (R/M cSCC) that is not amenable to surgery and/or radiation and/or systemic therapies.
MORE DETAILS ON THIS TRIAL:
17060 / NCT03284424 / PI TBD / STAR Trial / Open 10-11-2017 / Re-Open 11-27-2018
TRIAL AVAILABLE AT THESE LOCATIONS:
This STAR trial can be opened at any RMCC location as patients are identified.